Baseline Hormone Levels and Monitoring Strategies for Hormone Replacement Therapy in Premature Ovarian Insufficiency

Expected Early Follicular Hormone Levels

Estradiol remains low in the first 3 days of the menstrual cycle and begins to rise after day 3–5, reaching peak concentrations of approximately 150–200 pg/mL per mature follicle during the pre‑ovulatory period. 1

Simultaneous measurement of follicle‑stimulating hormone (FSH) and estradiol is recommended for diagnosing premature ovarian insufficiency (POI); a low estradiol level (< 50 pg/mL) together with an elevated FSH level (> 25 IU/L) confirms hypo‑estrogenism. 1, 3
If the initial assessment shows low estradiol and high FSH, the assay should be repeated after one month to verify persistent hypo‑estrogenism. 1

Blood sampling on cycle day 2–3 is advised to avoid confounding from the mid‑cycle estradiol surge or estrogen‑secreting ovarian cysts. 1
Day 2 measurements provide true baseline hormone values before initiating hormone replacement therapy, allowing clinicians to distinguish normal early‑follicular levels from pathological hypo‑estrogenism. 3, 1

Women using combined estrogen‑progestin contraception or long‑acting progestins must discontinue the antigonadotropic agent for at least three months before repeat hormonal testing, because such therapy falsely suppresses FSH. 1
Pregnancy must be ruled out before interpreting baseline FSH and estradiol results. 3

According to the American College of Endocrinology, FSH cannot be used as a sole marker to monitor the adequacy of estrogen replacement therapy, since inhibin also regulates FSH secretion. 4
Serum FSH may remain elevated despite adequate tissue estrogenization during hormone replacement therapy. 4
If menopausal symptoms persist after dose escalation or a change in route of administration (e.g., from oral to transdermal), measuring serum estradiol can guide further dose adjustment. 6

Physiological estradiol concentrations comparable to women in their early 40 s can generally be achieved with a 100 µg transdermal 17β‑estradiol patch or 2 mg oral estradiol. 3, 7
Women with premature ovarian insufficiency often require higher estrogen doses than those with natural menopause to attain satisfactory symptom relief. 3, 7